Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy. These thymidine kinase-defective isolates were sensitive in vitro to foscarnet. While combined therapy with ACV and interferon produced only partial clinical improvement, the in vitro effect of this combination against an ACV-resistant isolate from the patient was strongly synergistic. A short course (10-12 days) of intravenous foscarnet controlled severe ulceration, and clinical improvement lasted 6 months. After recurrence and further courses of foscarnet, however, the patient responded poorly, and subsequent HSV isolates were resistant to both ACV and foscarnet and hypersensitive to aphidicolin.
Birch
C J
CJ
Virology Department, Fairfield Hospital, Australia.
Tachedjian
G
G
Doherty
R R
RR
Hayes
K
K
Gust
I D
ID
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000212:Acyclovir / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology*; D016590:Aphidicolin; D003849:Deoxyguanosine / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D005260:Female; D017245:Foscarnet; D006561:Herpes Simplex / Q000150:complications* / Q000382:microbiology; D006801:Humans; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D018139:Simplexvirus / Q000187:drug effects*
D000998:Antiviral Agents; D004224:Diterpenes; D017245:Foscarnet; D016590:Aphidicolin; D003849:Deoxyguanosine; D010746:Phosphonoacetic Acid; D000212:Acyclovir